Adhera Therapeutics, Inc. is an emerging specialty biotech company, which is in the process of evaluating its focus including a return to drug discovery and development. The company is headquartered in Wake Forest, North Carolina. The firm is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The firm has two drug candidates: MLR-1019 and MLR-1023. The company is engaged in developing MLR-1023 (tolimidone) as a new drug for Type I Diabetes with a focus on C-peptide positive patients. Adhera also has exclusive rights to develop MLR-1023 for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation diseases and conditions. MLR-1023, a lyn kinase activator, has demonstrated clinical safety and tolerability in over 700 patients in Phase IIa and Phase IIb Type 2 diabetes studies. MLR-1019 (armesocarb) is a new class of drug for Parkinson's Disease.